Unveiling 3 Analyst Insights On Arcturus Therapeutics
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
Express News | Self-Amplifying Mrna Covid-19 Vaccine Demonstrates Superior Immune Response Compared With Mrna Vaccine at 12 Months Post-Vaccination
Arcturus Therapeutics, CSL's Updated Covid-19 Vaccine Approved in Japan